版本:
中国

BRIEF-Ocera Therapeutics says OCR-002 prevents progression of fibrosis in non-alcoholic fatty liver disease

April 12 Ocera Therapeutics Inc-

* Ocera Therapeutics announces presentation of data showing ocr-002 prevented progression of fibrosis in preclinical model of non-alcoholic fatty liver disease (nafld)

* Data supports potential for ocr-002 in treatment of non-alcoholic fatty liver disease

* Ocera Therapeutics - nafld rats treated with ocr-002 showed significant reduction in progression of fibrosis compared to untreated nafld rats Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐